Get the Stockscreener App
0.5121
2.94%
-0.0155
After Hours:
.52
0.0079
+1.54%
Enlivex Ltd stock is traded at $0.5121, with a volume of 370.49K.
It is down -2.94% in the last 24 hours and down -27.87% over the past month.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
See More
Previous Close:
$0.5276
Open:
$0.53
24h Volume:
370.49K
Relative Volume:
0.87
Market Cap:
$123.44M
Revenue:
-
Net Income/Loss:
$1.24B
P/E Ratio:
0.0201
EPS:
25.475
Net Cash Flow:
$-31.80M
1W Performance:
-11.71%
1M Performance:
-27.87%
6M Performance:
-37.48%
1Y Performance:
-56.60%
1-Day Range:
$0.5089
$0.541
1-Week Range:
$0.5089
$0.59
52-Week Range:
$0.5089
$2.10
Enlivex Ltd Stock (ENLV) Company Profile
Compare ENLV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Ltd
|
0.5121 | 132.55M | 0 | 1.24B | -31.80M | 25.48 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enlivex Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Ltd Stock (ENLV) Latest News
Discontinued operations of Enlivex Ltd. – DUS:1BT - TradingView
Preferred dividends of Enlivex Ltd. – DUS:1BT - TradingView
Enterprise value to revenue forward of Enlivex Ltd. – DUS:1BT - TradingView
Price to sales forward of Enlivex Ltd. – NASDAQ:ENLV - TradingView
Price to book forward of Enlivex Ltd. – NASDAQ:ENLV - TradingView
Enterprise value to EBIT forward of Enlivex Ltd. – NASDAQ:ENLV - TradingView
Enterprise value to EBITDA forward of Enlivex Ltd. – DUS:1BT - TradingView
Enlivex Ltd. Earnings and Revenue – DUS:1BT - TradingView
Enlivex Ltd. Actuals & Estimates (NASDAQ:ENLV) - TradingView
ENLV Forecast — Price Target — Prediction for 2027 - TradingView
1BT Forecast — Price Target — Prediction for 2027 - TradingView
Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gate exchange lists Enlivex treasury asset RAIN token - Investing.com
Gate exchange lists Enlivex treasury asset RAIN token By Investing.com - Investing.com India
Enlivex’s Primary Treasury Asset RAIN Token set for Listing on Major Exchange Gate - TipRanks
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume - The Manila Times
Enlivex (NASDAQ: ENLV) highlights RAIN listing on Gate and $1.14B treasury - Stock Titan
Enlivex token gets Gate listing, widening access to its $1.14B treasury asset - Stock Titan
Enlivex Ltd. (ENLV) Edges Higher – Key Levels to WatchPrice Target - dars.gov.et
Enlivex Therapeutics Ltd (ENLV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enlivex Values RAIN Token Treasury at $1.14 Billion as of June 20, 2026 - TipRanks
Form 6K Enlivex Therapeutics Ltd For: 22 June By Investing.com - Investing.com South Africa
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion - The Manila Times
[6-K] Enlivex Ltd. Current Report (Foreign Issuer) | ENLV SEC FilingForm 6-K - Stock Titan
Enlivex Reports $1.14 Billion Value in RAIN Token Holdings as of June 20, 2026 - Quiver Quantitative
Enlivex says its RAIN token treasury is worth about $1.14 billion - Stock Titan
Enlivex Therapeutics Ltd (ENLV) Institutional Confidence - TradingKey
ENLV Stockweekly outlook with no verified hook - AD HOC NEWS
Enlivex Therapeutics Ltd (ENLV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enlivex Therapeutics Ltd (ENLV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enlivex Therapeutics Ltd (ENLV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enlivex Therapeutics Ltd (ENLV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Enlivex Therapeutics Ltd (ENLV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enlivex Therapeutics Ltd (ENLV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ENLV Q4 2025 Earnings: Massive EPS Miss Highlights Challenging QuarterProfit Announcement - newsline.com
Enlivex Secures Australian Patent for Allocetra in Osteoarthritis Treatment - GuruFocus
Enlivex (ENLV) Slips Slightly as Stock Tests Key Support Near $0.63Positive Gamma - newsline.com
Enlivex receives Australian patent for osteoarthritis treatment - Investing.com
Enlivex receives Australian patent for osteoarthritis treatment By Investing.com - Investing.com Canada
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis - The Manila Times
Australian patent backs Enlivex cell therapy for knee osteoarthritis to 2040 - Stock Titan
Enlivex (ENLV) Shares Slide Over 6% as Stock Tests Key Support at $0.64Last Point Support - newsline.com
ENLV Q4 2025 Earnings: Deep Losses and Clinical Progress Amid Severe EPS MissEarnings Revision Upgrade - newsline.com
Enlivex Therapeutics stock (IL0011283620): Data monitoring, Nasdaq notice and next steps for investo - Ad-hoc-news.de
ENLV Q4 2025 Earnings: Significant EPS Miss Reflects Clinical-Stage DevelopmentHigh Estimate Range - newsline.com
Number of shareholders of Enlivex Ltd. – LSX:A119KH - TradingView
RAIN Highlights $200M Ecosystem Commitment, $100M Liquidity Expansion, and World Cup Growth Strategy Ahead of Version 2 Launch - GlobeNewswire Inc.
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026 - marketscreener.com
Enlivex brings longevity‑prediction markets pitch to $18T Paris summit - Stock Titan
Enlivex to present knee osteoarthritis trial data at EULAR By Investing.com - Investing.com South Africa
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026 - The Manila Times
Enlivex Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):